Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 10/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 4/20 | 0.35 |
| ▸ | SRC | P12931 | 3/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1129368 | 0.81 | NUDT1 (0.34) | NUDT1TNK2FGFR2BTKABL1 | |
| SCHEMBL17893144 | 0.81 | NUDT1 (0.34) | NUDT1TNK2FGFR2BTKABL1 | |
| SCHEMBL23044547 | 0.81 | BTK (0.48) | NUDT1TNK2BTKABL1SRC | |
| SCHEMBL31330580 | 0.78 | TNK2 (0.40) | TNK2BTK | |
| SCHEMBL31330632 | 0.78 | TNK2 (0.51) | NUDT1TNK2BTKABL1SRC | |
| SCHEMBL18099733 | 0.78 | ABL1 (0.53) | NUDT1TNK2BTKABL1SRC | |
| SCHEMBL23111989 | 0.78 | TNK2 (0.51) | TNK2BTKABL1SRCTLR7 | |
| SCHEMBL3535319 | 0.77 | — | — | |
| SCHEMBL18849916 | 0.76 | ABL1 (0.43) | NUDT1TNK2BTKABL1SRC | |
| SCHEMBL18849914 | 0.76 | ABL1 (0.43) | NUDT1TNK2BTKABL1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055366-A | GCN2 and PERK kinase modulators and methods of use thereof | 德西费拉制药有限责任公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4719606-A2 | GCN2 AND PERK KINASE MODULATORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024249493-A2 | GCN2 AND PERK KINASE MODULATORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024169871-A1 | BTK INHIBITOR AND USE THEREOF | 江苏威凯尔医药科技有限公司 | 2024-08-22 | — | — | WO | disclosed |
| CN-118515673-A | BTK inhibitor and application thereof | 江苏威凯尔医药科技有限公司 | 2024-08-20 | — | — | CN | disclosed |
| EP-3240572-B1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-112424203-B | Bruton's tyrosine kinase inhibitors | 正大天晴药业集团股份有限公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-112424203-A | Bruton's tyrosine kinase inhibitors | 正大天晴药业集团股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-108191871-B | Novel Bruton's tyrosine kinase inhibitor and preparation method and application thereof | 成都倍特药业有限公司 | 2020-02-18 | — | — | CN | disclosed |
| WO-2020015735-A1 | BRUTON TYROSINE KINASE INHIBITORS | 正大天晴药业集团股份有限公司 | 2020-01-23 | — | — | WO | disclosed |
| EP-1957496-B1 | BICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARM INC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-7648987-B2 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7648987-B2 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7648987-B2 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1957496-A2 | BICYCLIC PROTEIN KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| WO-2007064993-A2 | BICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064993-A2 | BICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | CDK1, MAP4K2, MAP4K3 | NUDT1 4135/4885TNK2 174/4885FGFR2 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.